<DOC>
	<DOCNO>NCT00006079</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use eflornithine may effective way prevent recurrence development cervical cancer . PURPOSE : Randomized phase II trial determine effectiveness eflornithine prevent cervical cancer patient cervical intraepithelial neoplasia .</brief_summary>
	<brief_title>Eflornithine To Prevent Cervical Cancer Patients With Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy eflornithine versus placebo cause regression patient cervical intraepithelial neoplasia . II . Compare qualitative quantitative toxicity treatment regimens patient . III . Establish biochemical tissue marker DNA content , PCNA , ras oncogene , EGFR , keratin involucrin intermediate biomarker end point squamous carcinogenesis patient . OUTLINE : This randomize , double blind , multicenter study . Patients randomize one three treatment arm . Arm I-II : Patients receive one two different dos oral eflornithine daily . Arm III : Patients receive oral placebo daily . Treatment continue 28 day absence disease progression unacceptable toxicity . Patients follow 28 day , 6 , 12 , 18 , 24 month . PROJECTED ACCRUAL : A total 180 patient ( 60 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>1 ) Women newly diagnose recurrent CIN grade 23 , involve area 3times large biopsy site . Patients must &gt; 18 year old , performance status less equal 2 ( Zubrod Scale ) predict life expectancy great equal 12 month . Patients must medically safe form contraception duration study . All patient must complete pretreatment evaluation , consent colposcopy cervical biopsy histologic evaluation 1 ) Patients may prior malignancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>cervical intraepithelial neoplasia grade 2</keyword>
	<keyword>cervical intraepithelial neoplasia grade 3</keyword>
	<keyword>Eflornithine</keyword>
</DOC>